SubscribeLogin
Published

TRexBio Announces $84 Million Series B

Summary by fundingblogger.com
SOUTH SAN FRANCISCO, CA, TRex Bio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, announced the close of an oversubscribed $84 million Series B financing round. The financing was led by Delos Capital. TRex Bio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, announced the close of an oversubscribed $84 million Series B financing round. The f…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

South San FranciscoSouth San Francisco
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal